Verrica Pharmaceuticals (VRCA) Accounts Payables (2017 - 2026)
Verrica Pharmaceuticals (VRCA) posted quarterly Accounts Payables of $2.2 million for Q1 2026, up 51.98% year-over-year from $1.4 million in Q1 2025, and up 5.84% quarter-over-quarter from $2.1 million in Q4 2025.
Verrica Pharmaceuticals (VRCA) Accounts Payables (2017 - 2026) Analysis & Trends
Verrica Pharmaceuticals' Accounts Payables history runs 10 years deep, the most recent figure standing at $2.2 million for Q1 2026.
- In Q1 2026, Accounts Payables rose 51.98% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $2.2 million (up 51.98% YoY), while the FY2025 annual figure was $2.1 million, up 9.28% from the prior year.
- Accounts Payables for Q1 2026 stood at $2.2 million, up from $2.1 million in the prior quarter.
- The five-year high for Accounts Payables was $2.5 million in Q1 2024, with the low at $137000.0 in Q3 2022.
- The 5-year median for Accounts Payables is $1.6 million (2025), against an average of $1.5 million.
- The sharpest annual moves came in 2022 and 2023: Accounts Payables sank 84.85% in 2022, then soared 1305.11% in 2023.
- Verrica Pharmaceuticals' Accounts Payables stood at $507000.0 in 2022, then jumped by 386.0% to $2.5 million in 2023, then declined by 23.05% to $1.9 million in 2024, then advanced by 9.28% to $2.1 million in 2025, then gained by 5.84% to $2.2 million in 2026.
- Business Quant data shows VRCA's Accounts Payables at $2.2 million in Q1 2026, $2.1 million in Q4 2025, and $1.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Verrica Pharmaceuticals | 102.80 Mn | 91.60 Mn | - | 1.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.60 Mn |
| Mar 31, 2026 | 2.19 Mn |
| Dec 31, 2025 | 2.07 Mn |
| Sep 30, 2025 | 1.59 Mn |
| Jun 30, 2025 | 2.32 Mn |
| Mar 31, 2025 | 1.44 Mn |
| Dec 31, 2024 | 1.90 Mn |
| Sep 30, 2024 | 966,000.00 |
| Jun 30, 2024 | 1.15 Mn |
| Mar 31, 2024 | 2.53 Mn |
| Dec 31, 2023 | 2.46 Mn |
| Sep 30, 2023 | 1.93 Mn |
| Jun 30, 2023 | 2.06 Mn |
| Mar 31, 2023 | 575,000.00 |
| Dec 31, 2022 | 507,000.00 |
| Sep 30, 2022 | 137,000.00 |
| Jun 30, 2022 | 714,000.00 |
| Mar 31, 2022 | 531,000.00 |
| Dec 31, 2021 | 845,000.00 |
| Sep 30, 2021 | 904,000.00 |